---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-061200"
form_type: "8-K"
ticker: null
cik: "0000786947"
company_name: "ACURA PHARMACEUTICALS, INC"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:32:19.438082+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Acura gets $200K loan from controlling shareholder; warns bankruptcy possible if no new funds by early June

## Summary
- AD Pharma loaned $200K on May 10; total principal now $5.62M at 5.25%, due June 30, 2024.
- Accrued interest ~$310K; default rate rises to 7.5% after 5-day grace.
- Without additional financing by early June 2024, Acura may scale back operations or seek bankruptcy protection.
- AD Pharma directly owns ~65% of Acura common stock; Mr. Schutte (AD Pharma manager) owns ~13% directly.
- Loan proceeds used for day-to-day operations; no assurance further funding will be available.

## SEC filing metadata
- accession: 0001104659-24-061200
- form_type: 8-K
- cik: 0000786947
- company_name: ACURA PHARMACEUTICALS, INC
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/786947/000110465924061200/0001104659-24-061200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/786947/000110465924061200/tm2414484d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-061200
- JSON: https://secwatch.observer/filing/0001104659-24-061200.json
- Plain text: https://secwatch.observer/filing/0001104659-24-061200.txt

## Key facts
- Debt Financings
  ACURA PHARMACEUTICALS, INC incurred loan of $200,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing June 30, 2024.
  - Instrument: loan
  - Principal: $200,000
  - Counterparty: Abuse Deterrent Pharma, LLC
  - Rate: 5.25%
  - Maturity: June 30, 2024
  - Event: incurrence
  source text: On May 10, 2024 we received a $200,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”). This loan combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $5,619,279 with accrued interest of approximately $310,000, bears interest at 5.25%, and matures on June 30, 2024, at which time all principal and interest is due (“Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/786947/000110465924061200/0001104659-24-061200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.